



Resource impact summary report

Resource impact

Published: 14 July 2026

www.nice.org.uk

Contents

Resource impact summary report 3

 Guidance recommendation 3

 Financial and capacity resource impact..... 3

 Eligible population for pembrolizumab with chemoradiotherapy 4

 Treatment options for the eligible population 4

 Key information..... 5

 About this resource impact summary report..... 5

Resource impact summary report

This summary report is based on the NICE assumptions used in the [resource impact template](#). Users can amend the 'Population and treatments' and 'Unit costs' worksheets in the template to reflect local data and assumptions.

Guidance recommendation

See [NICE's recommendation on pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer](#).

Financial and capacity resource impact

The key drivers of resource impact are that:

- Pembrolizumab is given in addition to chemoradiotherapy (cisplatin plus radiotherapy) so use of chemoradiotherapy is not expected to change.
- Pembrolizumab continues as a monotherapy beyond the usual treatment duration for chemoradiotherapy.

The company has a [commercial arrangement](#). This makes pembrolizumab available to the NHS at a discount.

Users can input the confidential price of pembrolizumab and amend other variables in the [resource impact template](#).

The payment mechanism for the technology is determined by the responsible commissioner and depends on whether the technology is classified as high cost.

The treatment duration for pembrolizumab with chemoradiotherapy and the rates and costs of adverse events are commercial in confidence so we cannot show the impact on capacity. Users can enter the estimated treatment duration into the resource impact template to calculate the impacts.

For further analysis or to calculate the financial and capacity impact from a commissioner (national) and provider (local) perspective, see the [resource impact template](#).

Eligible population for pembrolizumab with chemoradiotherapy

Table 1 shows the population who are eligible for pembrolizumab with chemoradiotherapy and the number of people who are expected to have pembrolizumab with chemoradiotherapy in each of the next 3 years, excluding forecast population growth.

Table 1 Population expected to be eligible for and have pembrolizumab with chemoradiotherapy in England

Eligible population and uptake	Number of people eligible for pembrolizumab with chemoradiotherapy	Uptake for pembrolizumab with chemoradiotherapy (%)	Number of people starting treatment each year
Current practice without pembrolizumab with chemoradiotherapy	274	0	0
Year 1	274	40	110
Year 2	274	50	137
Year 3	274	65	178

The uptake for pembrolizumab with chemoradiotherapy is based on information from NHS England and the company.

Treatment options for the eligible population

The comparator treatments for the eligible population are chemoradiotherapy, the use of chemoradiotherapy is not expected to change as it will be given with or without pembrolizumab and the treatment duration is the same. Pembrolizumab and cisplatin are both given intravenously.

For more information about the treatments, such as dose and average treatment duration, see the [resource impact template](#).

Key information

Table 2 Key information

Time from publication to routine commissioning funding	90 days
Programme budgeting category	02G cancer, gynaecological
Commissioner	NHS England
Provider	NHS hospital trusts
Pathway position	First line

About this resource impact summary report

This resource impact summary report accompanies the [NICE technology appraisal guidance on pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer](#) and should be read with it.

ISBN: 978-1-4731-9610-0